Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 13 Oct 2007):

Possible glutamatergic and lipid signalling mechanisms in ECT-induced retrograde amnesia: experimental evidence for involvement of COX-2, and review of literature.

Full Abstract

We sought to explore nonselective vs. selective COX mechanisms in ECS-induced retrograde amnesia using indomethacin and celecoxib as in vivo probes. Adult Wistar rats (n=72) which showed adequate learning on a passive avoidance task received 5 once-daily 30 mC true or sham ECS. During the learning and ECS periods, indomethacin (4 mg/kg/day), celecoxib (15 mg/kg/day), or vehicle were orally administered. One day after the fifth ECS, recall of pre-ECS learning was tested. There were no baseline or pre-ECS differences in learning between groups. ECS seizure duration did not differ across groups. ECS-treated rats showed impaired recall in the vehicle but not indomethacin and celecoxib groups. Celecoxib but not indomethacin significantly protected against ECS-induced retrograde amnesia. We interpret these results as follows: ECS may impair cognition by pathologically upregulating glutmatergic signalling, thereby causing cation and water influx, oxidative stress, and saturation of hippocampal LTP. These may result from glutamatergic disinhibition through COX-2-mediated removal of endogenous cannabinoids, and by ECS-activated, NMDA-mediated upregulation of platelet activating factor and COX-2 signalling pathways. Thus, indomethacin and celecoxib, by inhibiting COX-2, may protect against ECS-induced amnesia. Furthermore, COX-2 mediated increase in hippocampal kynurenic acid may impair glutamate-dependent learning and memory processes at ionotropic glutamatergic receptor sites; the inhibition of kynurenic acid synthesis by celecoxib and its induction by indomethacin may explain the greater benefits with celecoxib. These findings suggest new avenues for the study of the neurobiology of ECT-induced amnesia and the attenuation thereof.

 

Author information

Author/s: Andrade, Chittaranjan (C); Singh, Nagendra M (NM); Thyagarajan, S (S); Nagaraja, Nandakumar (N); Sanjay Kumar Rao, N (N); Suresh Chandra, J (J);

Affiliation: Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India. andradec(-atsign-)gmail.com

Journal and publication information

Publication Type: Journal Article; Review

Journal: Journal of psychiatric research (J Psychiatr Res), published in England. (Language: eng)

Reference: 2008-Aug; vol 42 (issue 10) : pp 837-50

Dates: Created 2008/06/16; Completed 2008/08/25;

PMID: 17937934, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Associated Chemicals: Pyrazoles (0) ; Receptors, N-Methyl-D-Aspartate (0) ; Sulfonamides (0) ; celecoxib (169590-42-5) ; Kynurenic Acid (492-27-3) ; Indomethacin (53-86-1) ; Glutamine (56-85-9) ; Cyclooxygenase 2 (EC 1.14.99.1) ; Ptgs2 protein, rat (EC 1.14.99.1)

Related articles

These are the highest related articles currently in the database:

See 100+ related articles.

Related Article Map

4/29/1995
6/15/2008
Higher Relevance Score (16)
Lower Relevance Score (9)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.

© Advanogy LLC 2003-2009 - All rights reserved. Terms of Use | Contact Us | Index